Six numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 2 other studies
the abstract, start to end
… on major bleeding is very uncertain (RR 0.98, 95% CI 0.06 to 15.53; very …
… major or disabling stroke (RR 0.14, 95% CI 0.02 to1.16; 1 study, 793 participants) and stroke-related mortality (RR 0.57, 95% CI 0.17 to 1.94; 1 study, …
… pravastatin, and rosuvastatin; RR 0.36, 95% CI 0.09 to 1.53; 5 studies, 2235 participants) stroke-related mortality (lovastatin and pravastatin; RR 0.25, 95% CI 0.03 to 2.29; 2 studies, 1366 participants), and adverse events (fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin; RR 0.76, 95% CI 0.53 to1.10; 7 studies, …
← favours treatmentfavours comparator →
could be chanceAdverse events & safety
RR 0.980.06–15.5
Blood pressure
RR 0.140.02–1.16
Blood pressure
RR 0.570.17–1.94
Cardiovascular events
RR 0.360.09–1.53
Cardiovascular events
RR 0.250.03–2.29
Adverse events & safety
RR 0.760.53–1.10
StatinsOther lipid agentsAntihypertensivesAntiplatelet & anticoagulantBlood pressureCardiovascular eventsAdverse events & safety
Antihypertensives × blood pressurehelps?replicated
unlikelylikely
0.96not counted
Other lipid agents × cardiovascular eventshelps?settled
unlikelylikely
0.80not counted
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.86not counted
← favours treatmentfavours comparator →
1 / 5